The genetic case for cardiorespiratory fitness as a clinical vital sign and the routine prescription of physical activity in healthcare

Ken B. Hanscombe[1, 4], Elodie Persyn[1], Matthew Traylor[2], Kylie P. Glanville[4], Mark Hamer[3], Jonathan R. I. Coleman[4], Cathryn M. Lewis[1, 4]

[1]Department of Medical & Molecular Genetics, King's College London, London, United Kingdom, [2]Queen Mary University of London, London, United Kingdom, [3]Institute of Sport Exercise & Health, Division of Surgery and Interventional Science, University College London, London, United Kingdom, [4]Social, Genetic and Developmental Psychiatry Centre, King's College London, London, United Kingdom

Ken B. Hanscombe ken.b.hanscombe@kcl.ac.uk (corresponding author)
Elodie Persyn elodie.persyn@kcl.ac.uk
Matthew Traylor m.traylor@qmul.ac.uk
Kylie P. Glanville kylie.glanville@kcl.ac.uk
Mark Hamer m.hamer@ucl.ac.uk
Jonathan R. I. Coleman jonathan.coleman@kcl.ac.uk
Cathryn M. Lewis cathryn.lewis@kcl.ac.uk

Abstract

Background: Cardiorespiratory fitness (CRF) and physical activity (PA) are well-established predictors of morbidity and all-cause mortality. However, CRF is not routinely measured and PA not routinely prescribed as part of standard healthcare. The American Heart Association (AHA) recently presented a scientific case for the inclusion of CRF as a clinical vital sign based on epidemiological and clinical observation. Here, we leverage genetic data in the UK Biobank (UKB) to strengthen the case for CRF as a vital sign, and make a case for the prescription of PA.

Methods: We derived two CRF measures from the heart rate data collected during a submaximal cycle ramp test: CRF-vo2max, an estimate of the participants' maximum volume of oxygen uptake, per kilogram of body weight, per minute; and CRF-slope, an estimate of the rate of increase of heart rate during exercise. Average PA over a 7-day period was derived from a wrist-worn activity tracker. After quality control, 70,783 participants had data on the two derived CRF measures, and 89,683 had PA data. We performed genome-wide association study (GWAS) analyses by sex, and post-GWAS techniques to understand genetic architecture of the traits and prioritize functional genes for follow-up.

Results: We found strong evidence that genetic variants associated with CRF and PA influenced genetic expression in a relatively small set of genes in heart, artery, lung, skeletal muscle, and adipose tissue.

These functionally relevant genes were enriched among genes known to be associated with coronary artery disease (CAD), type 2 diabetes (T2D), and Alzheimer's disease (three of the top 10 causes of death in high-income countries) as well as Parkinson's disease, pulmonary fibrosis, and blood pressure, heart rate, and respiratory phenotypes. Genetic variation associated with lower CRF and PA was also correlated with several disease risk factors (including greater body mass index, body fat and multiple obesity phenotypes); a typical T2D profile (including higher insulin resistance, higher fasting glucose, impaired beta-cell function, hyperglycaemia, hypertriglyceridemia); increased risk for CAD and T2D; and a shorter lifespan.

Conclusions: Genetics supports three decades of evidence for the inclusion of CRF as a clinical vital sign. Given the genetic, clinical, and epidemiological evidence linking CRF and PA to increased morbidity and mortality, regular measurement of CRF as a marker of health and routine prescription of PA could be a prudent strategy to support public health.

Keywords

cardiorespiratory fitness, physical activity, genetics, genome-wide association, UK Biobank

Background

Cardiorespiratory fitness (CRF) and physical activity (PA) are well-established predictors of morbidity and mortality (1, 2). CRF is such a strong predictor of cardiovascular health, all-cause mortality, and mortality attributable to various cancers, that in 2016 the American Heart Association (AHA) put forward a scientific case for measuring CRF as a clinical vital sign (3). The AHA recommended that, "(at) a minimum, all adults should have CRF estimated each year (...) during their annual healthcare examination". Non-exercise testing methods for estimating CRF make this possible in a clinical setting (4). The AHA also noted that measurement of CRF provides "clinicians the opportunity to counsel patients regarding the importance of performing regular physical activity". That exercise is medicine, preventative and curative, has been known from antiquity – Hippocrates wrote the earliest known prescription for exercise about 2000 years ago (5). Today however, we do not yet routinely prescribe PA, nor do we measure CRF as part of a standard clinical assessment.

Sedentary lifestyles are a significant public health problem. For example, physical inactivity and poor diet were the second leading modifiable, behavioural cause of death in the US in 2000 and are expected to overtake tobacco to become the leading cause (6). Worldwide, physical inactivity was estimated to account for about 10% of premature mortality in 2008, an effect size similar to smoking and obesity (7). In 2013, the economic burden due to direct health-care costs, productivity losses, and disability-adjusted life-years attributable to physical inactivity was estimated at US$53.8 billion (8). This economic burden is reflected in the prevalence of physical inactivity worldwide: 28% in 2016 (23% for men, 32% for women) (9). Most people

do not know what the recommended activity guidelines to maintain good health are. A UK British Heart

Foundation (BHF) survey estimated about 60% of adults in the UK do not know the recommended minimum

level of PA (10). Modifiable physiological characteristics like CRF and behaviours like regular exercise are

affected by both environmental and genetic factors. Genetic factors, not addressed in the AHA review, can

influence CRF and PA through multiple mechanisms including appetite for leisure activity, physiological

response to exercise, and CRF response to PA. Critically, genetics can be leveraged to identify links

between CRF, PA, and disease. Here we present the genetic case for the measurement of CRF as a clinical

vital sign, and the routine prescription of PA.

CRF is typically measured with incremental exercise (resistance or workload) on a treadmill or cycle

ergometer. In a sub-maximal test, CRF is estimated from extrapolating the workload to the age-estimated

maximum heart rate. PA has most often been measured by self-report. Previous research has shown that

CRF and PA are familial, with family and twin study estimates of their heritability varying widely (CRF:

h^2=0.25 – 0.65 (11); PA: h^2=0 – 0.78, and 0.48 in the only study that objectively measured PA (12)). There

has been some interest in variation in CRF response to exercise. Several candidate gene studies and one

genome-wide association study (GWAS) have reported genetic variants associated with baseline CRF, or CRF

change in response to exercise, but none was genome-wide significant or reliably replicated (13-15). Two

GWASs of PA in the UK Biobank (UKB) reported three loci associated with accelerometer-measured 7-day

average PA (SNP heritability, h^2_{SNP}=0.14), and none with self-reported PA (16, 17). The genetic contribution

to CRF is poorly characterised, and our current understanding of the genetics of PA has not examined

differences by sex.

In this study, we performed the largest genome-wide association analysis of CRF, a GWAS of PA, and

related their genetic risk profiles to the known genetic risk for anthropomorphic phenotypes, metabolic

traits, and chronic diseases. CRF and PA were objectively measured in the UKB (18). Given the multitude of

mechanisms by which PA and CRF affect biology (3, 15, 19), the differences in physiognomy (e.g., body fat

distribution (20, 21)), behavioural dynamics (e.g., motivators and context preferences (22)), we

investigated sex-specific as well as sex-combined CRF and PA phenotypes. Previous UKB analyses of PA have

reported genetic correlations between the sexes and included sex as a covariate in combined analyses (17),

which by design identifies only genetic factors common to both sexes. Here, we also investigated the

potential functional effects of sex-specific associations. Our aim in this study was to characterise the

genetic contribution to CRF and PA highlighting genetic links to disease, and thus to strengthen the case for

the inclusion of CRF as a clinical vital sign and make more cogent the argument for routine prescription of

regular PA in healthcare.

Methods

Sample

UK Biobank. The UK Biobank (UKB) is a research study of over 500,000 individuals from across the United Kingdom. Participants aged 40 to 69 were invited to attend one of 22 assessment centres between 2006 and 2010. A comprehensive range of health-related data has been collected at baseline and follow up, including disease diagnoses and lifestyle information, with blood samples taken for genome-wide genotyping and a biomarker panel. Further data are available in follow up studies on different subsets of UKB participants, including CRF and PA data. All participants provided electronic signed consent (18, 23).

After selecting the European subsample (the largest cluster from a 4-means clustering of the first 2 UKB-derived principal components), and phenotype and genotype QC described below, we had 70,783 (34,419 male, 36,364 female) participants with CRF data, and 89,683 (39,352 male, 50,331 female) participants with PA data. Additional file 1: **Table S1** shows details of the derivation of the final GWAS sample.

Phenotypes

Cardiorespiratory fitness - submaximal cycle ramp test.

CRF was assessed with a submaximal cycle ramp test which used a stationary bicycle and 4-lead electrocardiograph (ECG) to record heartrate data during pre-test, exercise and rest phases (approximately 15 seconds, 6 minutes, and 1 minute respectively). The cycle test procedure is described in detail in the UKB Cardio Assessment document (24). Cycle ramp test data were collected at two instances: from August 2009 at the end of the initial assessment visit 2006–2010 (instance 0), and the first repeat assessment visit 2012–2013 (instance 1). Participants performed an exercise protocol determined by their risk level, *Program Category* (UKB field 6024): 'minimal', 'small', 'medium', or 'high'. The cycle ramp test included a 'Pre-test', 'Exercise', and 'Recovery' phase. We used data from the 'Exercise' phase only, within which, only 'minimal' and 'small' risk categories included a workload ramp (increase in workload). We selected samples in the 'minimal', 'small', and 'medium' risk categories, with *ECG Bike Method for Fitness Test* (6019) = 'Bicycle' (Additional file 1: **Table S2**), modelling heart rate data from the 4-minute workload ramp for the 'small' and 'minimal' risk groups, and the full 6-minute constant work load for the 'medium' risk group. We also included risk category as a covariate in the genetic association analyses.

The raw heart rate data were noisy (Additional file 1: **Figure S1**, panel **A**, shows raw heart rate data for 1,000 random participants). Participants were instructed to cycle at a cadence of 60 revolutions per minute (RPM) and we selected workload and heart rate data where participants cycled in the range 35-125 RPM (Additional file 1: **Figure S1**, panel **B**), within the manufacturer guaranteed range for cycle ergometer workload accuracy. Finally, we selected samples with a minimum of 20 observations of heart rate, workload, and cadence within the 'Exercise' phase of the test, and applied a Butterworth filter to the heart rate data (**Figure 1**). Full cycle ramp test QC is described in the supplementary Methods and listed in Additional file 1: **Table S1**.

From this data, we derived two measures: *CRF-vo2max*, an estimate of the maximum volume of oxygen
uptake per kilogram of body weight per minute; and *CRF-slope*, the rate of increase of heart rate.
Specifically, we fit a linear model to workload and heart rate and extrapolated from the linear model to
predict workload at the age-estimated maximum heart rate (HR·age·max = 208 – 0.7 * age, where age is age
when attended assessment centre). Maximum workload relative to body weight in kilograms, or relative
power (watts/kg), was then used as a proxy for CRF-vo2max:

$$CRF\text{-}vo2max = WL\text{·}HR\text{·}max \ / \ weight$$

Where WL·HR·max is extrapolated work load at age-estimated maximum heart rate. The coefficients 208
and 0.7 for age-estimated maximum heart rate are commonly used constants and were used in previous
studies of CRF in the UKB (25-28).

For CRF-slope, we fitted a linear model to the Butterworth-filtered heart rate signal for each participant
and retained the slope, β_1, as rate of increase of heart rate (**Figure 1**):

$$HR \sim \beta_0 + \beta_1 * trend$$

Where HR is heart rate and 'trend' refers to the time points at which repeated measurements of heart rate,
workload, and cadence were taken within each phase of the submaximal cycle ramp test (**Figure 1**).
Samples with negative slopes were excluded.

Physical activity - wrist-worn accelerometer.

PA in the UKB was measured continuously over a period of 7 days with a wrist-worn accelerometer in
103,712 participants, as an add-on measure after the initial assessment between June 2013 and January
2016. We used a wear-time adjusted 7-day average PA and filtered participants on the following test-
specific variables: *Data quality, good wear-time* (90015)='Yes', *Data quality, good calibration* (90016)='Yes',
and no *Data problem indicators* (90002). Finally, we excluded samples with PA (accelerometer) > 100
milligravities (mg). General PA quality control and calibration of raw accelerometer data and calculation of
derived activity level are described in detail elsewhere (29).

Disease frequency

The top 10 global causes of death in high-income countries in 2016, as reported by the World Health
Organization (WHO), are shown in Additional file 1: **Table S3**, along with the relevant International
Classification of Diseases revision 10 (ICD-10) codes. Ischaemic heart disease was the number 1 global cause
of death among high-income countries; lower respiratory tract infections, ranked 6th, was the only
communicable cause of death on the list. We used UKB in-patient hospital episode statistics (diagnoses
recorded in ICD-10 codes) to retrieve disease frequency for the top 10 global causes of death, among the

subsample with CRF or PA data (Additional file 1: **Table S3** includes ICD-10 codes). We ranked participants

by level of the phenotypes CRF-vo2max, CRF-slope, and PA after correcting for age and socioeconomic

status (SES, Townsend deprivation index), divided the participants into ten approximately equal-sized

groups, and calculated the proportion in each group with a main or secondary diagnosis (made during a

hospital in-patient admission) for each of the 10 query diseases. ICD-9 diagnoses were not included. Firstly,

it is not clear how to map ICD-9 codes onto the ICD-10 codes provided by the WHO. Secondly, ICD-9 codes

were observed at very low frequencies: 1 sample with CRF data, and 40 with PA data, were diagnosed with

ischaemic heart disease (ICD-9 codes starting with 41[0-9]), the most prevalent of the top 10 global causes

of death. Diagnoses were potentially received both before and after the cycle ramp test and the week in

which participants wore the physical activity tracker, and we made no distinction between incident and

prevalent disease. This analysis was performed separately in males and females, since there are differences

in both disease prevalence, and in phenotype distribution by sex.

Genetic analyses

The full UKB sample were genotyped on one of two custom Applied Biosystems genotyping arrays: 49,950 on

the UK Biobank Lung Exome Variant Evaluation (UK BiLEVE) Array, and 438,427 on the UK Biobank Axiom

Array. The genetic data underwent standard GWAS QC and were imputed using IMPUTE4 to three reference

panels by the UKB: the Haplotype Reference Consortium (HRC) and the merged UK10K and 1000 Genomes

phase 3 reference panels. General genotyping considerations, raw genotype data QC, and genetic

imputation procedures in the UKB are described in detail elsewhere (18). Details of available genetic data

and associated metadata are described in UKB Resource 664 (30).

From UKB-supplied sample QC information, we excluded gender mismatches, samples with putative sex

chromosome aneuploidy or excess relatives, and heterozygosity and missingness outliers. We performed

linear mixed model association on the residual of each trait regressed on the covariates age, age^2, sex (for

sex-combined analyses), array, centre, and the first 10 principal components calculated on subsamples with

data on the trait of interest. Additionally, for CRF phenotypes, we included the covariates risk category

(corresponding to CRF test protocol) and number of trend entries (number of observations). Full details of

GWAS QC and association parameters, alternative models including BMI, and alcohol and smoking as

covariates, and post-GWAS analyses including transcriptome-wide association (TWAS) and colocalization,

gene-set enrichment, and genetic correlation, are included in the supplementary methods. We used the

standard p=5x10^{-8} as our genome-wide significant threshold, a conservative Bonferroni-corrected p-value

for TWAS significance correcting for all genes tested in all tissues (p=0.05/75,486=6.6x10^{-7}), and a false-

discovery rate (FDR) correction for gene-set enrichment and genetic correlation accepting FDR-adjusted p-

values<0.05 as significant.

Analysis tools

For data analysis and figure creation we used both R (31) and Python 3 (32), in conjunction with the
bioinformatic pipeline software Snakemake (33). We used the R package ukbtools (34) to parse all UKB
data. Genetic data analyses were performed using FlashPCA (35), BOLT-LMM (36), PLINK 1.9 and 2.0 (37) ,
LDSC (38), FUSION (39), and the web-based tools FUMA (40), LD Hub (41), and LDlink (42).
242
243
244 ## Results
245
246 ### Descriptive statistics and smoking and alcohol drinking status
247
Descriptive statistics for the CRF and PA phenotypes showed higher values for CRF-vo2max in males, and
higher CRF-slope and PA in females (Additional file 1: **Table S4**). Correlations between CRF and PA
phenotypes, and age and BMI were all modest and negative (r=-0.02 – -0.27), except for CRF-slope and age
which had a small positive correlation in females (r=0.13, p=1.2×10^{-144}) (Additional file 1: **Figure S2**).
Combined-sex sample correlations between CRF-vo2max and CRF-slope, and SES were not significant; the
PA and SES, and sex-specific correlations for all three traits were significant but small ($| r | <= 0.03$). In the
combined-sex sample, phenotypic correlations between our three traits were in the directions expected.
CRF-vo2max and PA had a modest positive correlation (r=0.25, p=1.5×10^{-195}, among the subsample who
performed both the submaximal cycle ramp test and participated in the 7-day PA monitoring, N=13,561).
CRF-slope and PA were not significantly correlated (r=-0.01, p=0.11, N=13,561). The two fitness
phenotypes, CRF-vo2max and CRF-slope were negatively correlated (r=-0.39, p<0.001, N=70,783).
259
260 As a proxy for true resting heart rate, heart rate at the beginning of the exercise phase of the cycle ramp
261 test was negatively correlated with CRF-vo2max (r=-0.33, p<0.001), and had a near zero correlation with
262 CRF-slope (r=-0.03, p=3.8×10^{-13}).
263
Smoking and alcohol drinking status are sometimes considered confounding factors in analyses of CRF and
PA. In our data, there were small differences in mean CRF-vo2max, CRF-slope, and PA by smoking and
drinking status (Additional file 1: **Table S5**), which contributed little to trait variance in linear regression
models of all three phenotypes ($\Delta R^2 <= 0.005$ compared to a base model of age and sex, Additional file 1:
Table S6). We chose not to adjust for the effects of smoking and drinking status in order to obtain unbiased
estimates of the genetic factors on CRF and PA. There is evidence that correcting for heritable covariates
can lead to biased estimates of the influence of genetic factors (43).
271
272 ### Disease frequency
273
274 For the top 10 global causes of death in high-income countries in 2016, as reported by the World Health
275 Organization (WHO), **Figure 2** shows the frequency at which each disease was observed in the UKB by level
276 of CRF-vo2max, CRF-slope, and PA (after correcting for age and SES). Given the difference in the

277 phenotype distributions of the male and female subsamples, and the inherent difference in disease
278 frequency by sex, disease frequency has to be interpreted separately by sex.
279
280 *Disease frequency by CRF*
281
With increasing levels of CRF-vo2max, there were reductions in diagnosis frequency for ischaemic heart
disease (CAD) (male: 12.0-6.1%, female: 4.9-1.5%), stroke (male: 1.5-0.7%, female: 0.6-0.4%), chronic
obstructive pulmonary (COPD) (male: 1.5-0.3%, female: 1.1-0.3%), lower respiratory tract infection (LRTI)
(male: 2.5-1.0%, female: 2.0-1.2%), diabetes mellitus (male: 5.0-1.8%, female: 2.4-0.7%), and kidney
diseases (male: 1.4-0.8%, female: 1.0-0.6%). The largest differences were observed for CAD and diabetes,
with the starkest reductions for all disease often seen within the lowest 4 deciles of CRF-vo2max.
288
289 CRF-slope showed reduction in disease for CAD (male: 9.2-5.6%, female: 2.6-1.5%) and diabetes (male: 4.5-
290 2.4%, female: 1.5-0.6%). The relationships with other disease diagnoses were more noisy.
291
292 *Disease frequency by PA*
293
Disease diagnosis by level of PA showed similar patterns to CRF-vo2max, with a continued decile-to-decile
reduction in disease across the range of PA from least to most physically active. With increasing PA we
observed reductions in CAD (male: 9.3-2.5% female: 3.0-1.0%), stroke (male: 2.1-0.4%, female: 1.0-0.2%),
COPD (male: 1.8-0.2%, female: 1.1-0.3%), LRTI (male: 2.8-0.8%, female: 2.0-1.0%), diabetes mellitus (male:
6.0-0.7%, female: 3.7-0.4%), and kidney diseases (male: 2.4-0.9%, female: 1.3-0.5%). Like CRF-vo2max, the
greatest reductions were seen in CAD and diabetes mellitus.
300
301 **Genetic associations**
302
303 Genome-wide association studies were performed for CRF-vo2max, CRF-slope, and PA with results for male,
304 female, and the combined sample (**Figure 3**). An annotated list of the independent genome-wide
305 significant variants, determined by LD clumping of the association results, is included in **Table 1**. Additional
306 file 1: **Figures S3-S37** are the regional plots for each sex-combined GWAS signal peak, and sex-specific
307 GWAS signal peaks where there was evidence of heterogeneity.
308
309 <insert **Table 1** here>
310
311 *Sex-combined results*
312
We found twelve significant SNPs for CRF-vo2max and eight independent SNPs for CRF-slope, in the
combined sample (**Table 1**). For PA, we found nine significant SNPs. However, three of these were on
chromosome 17, two of which are situated within the large 17q21.31 inversion polymorphism (43,624,578 –
44,525,051 MB, human genome build 37 coordinates) and may not reflect independent causal variants (44,

45). We replicated two of the three previously reported PA GWAS significant SNPs (17), rs2696625 (chr17)
and rs59499656 (chr18) , and tagged the third rs564819152 (chr10) through LD with rs34719019 (chr10),
r^2=0.78 in 1000 Genomes EUR (Additional file 1: **Table S7**).

Sex-specific results

For CRF-vo2max we found four male genome-wide significant SNPs, three of which showed no evidence of
heterogeneity and were associated (directly or indirectly through LD) in the combined sample: rs9809798
(r^2=0.79 with rs6801957, chr3), rs111299422 (chr5), rs1006545 (r^2=0.97 with rs11190709, chr10). rs41317306
(chr14) however, showed no evidence for association in females (p=5.1x10^{-1}), or the combined sample
(p=1.6x10^{-4}), and significant effect size heterogeneity (Q=22.13, p<0.001). However, the regional plot for
rs41317306 did not show support from correlated SNPs (Additional file 1: **Figure S11**)

For CRF-slope, the one female signal rs111299422 (chr5) was significant in the combined sample, but
showed evidence of heterogeneity (Q=8.37, p=3.8x10^{-3}). There were two male specific SNPs: rs1006545
(chr10) was indirectly associated in the combined sample (r^2=0.97 with 10:102554618_AT_A) and showed
no evidence of heterogeneity. rs1741294 (chr20) showed no evidence of association in females (p=6.0x10^{-1})
or the combined sample (p=4.2x10^{-4}), and significant effect size heterogeneity (Q=7.96, p=4.8x10^{-3}).

For PA, there were four SNPs associated in the female sample, two of which were associated in the
combined sample, rs62055696 (chr17) and 17:44262581_A_C (r^2=0.70 with rs62055696, chr17), and showed
no evidence of heterogeneity. The two female signals on chromosome 16 signals rs75986475 and rs13329850
were uncorrelated (r^2=0.0005), showed significant heterogeneity (Q=8.51, p=3.5x10^{-3}; Q=16.98, p<0.001
respectively), and no evidence of association in males (p=3.3x10^{-1}, p=4.5x10^{-1} respectively) or the combined
sample (p=1.3x10^{-6}, p=7.6x10^{-4} respectively). The male-specific SNP identified in PA, rs78661713 (chr2),
showed no evidence for association in females (p=6.1x10^{-1}) or the combined sample (p=5.9x10^{-4}), and
significant heterogeneity (Q=20.63, p<0.001).

Genes to prioritize for experimental follow-up

For each trait, we report genes identified as both *functional* candidates by TWAS and colocalization
analysis, and *positional* candidates (**Table 1**) or gene-based association candidates (Additional file 1: **Table**
S8). We then report any additional noteworthy TWAS-significant functional candidates. The functional
candidates reported below all passed the TWAS multiple testing threshold (16 for CRF-vo2max, 10 for CRF-
slope, and 24 for PA), and are shown in **Figure 4**. Where functional candidates were also implicated in the
gene-based association test these are indicated in **Figure 4**. The full list of significant genes from the gene-
based test of association are shown in Additional file 1: **Table S8**.

CRF-vo2max

All functional candidates were located within cytochrome band 17q21.31, within or near the chromosome

17 inversion. In particular, five functional candidates were identified in the gene-based association and had

a high probability of a shared SNP driving both the CRF-vo2max association and expression in the listed

tissues (PP4 range=0.94 – 0.99, **Figure 4**): *WNT3* (Wnt family member 3) in aorta, heart (atrial appendage),

lung and skeletal muscle; *MAPT* (microtubule associated protein tau) in brain and lung; *LRRC37A2* (leucine

rich repeat containing 37A2) in and *LRRC37A* (leucine rich repeat containing 37A) in adipose (subcutaneous

and visceral omentum), artery (aorta and tibial), heart (atrial appendage and left ventricle), and skeletal

muscle; and *CRHR1* (corticotropin releasing hormone receptor 1) in adipose (subcutaneous and visceral

omentum) and skeletal muscle. Notable GWAS catalog associations for this set of genes include disease

(atrial fibrillation (46), diabetes mellitus, and coronary artery disease (47), Parkinson's (48), and

Alzheimer's disease (49)), lung function (FEV1, FVC (50), peak expiratory flow (51)), heart and

electrocardiography measures (QRS measures (52), cardiac arrhythmia (53)), and blood phenotypes (systolic

blood pressure, eosinophil count (54), haemoglobin level (55), haematocrit (56), red blood cell density

(57)).

CRF-slope

Positional candidate *ACHE* (acetylcholinesterase), implicated by rs4582488 (52.87kb upstream), was

significantly associated with expression in adipose (subcutaneous, visceral omentum), artery (aorta,

coronary, and tibial), and heart (atrial appendage) tissue. Each of these tissue associations had high

probability of a shared SNP driving both the CRF-slope association and expression (PP4 range=0.79 – 0.84).

ACHE has notable reported associations with resting heart rate (58), heart rate response to exercise and

recovery (59), electrocardiography (60), diastolic blood pressure (61), and diabetes mellitus (62).

Three functional candidates were also significant in the gene-based association: *TRIP6* (thyroid hormone

receptor interactor 6) with high probability of a shared SNP driving both CRF-slope association and

expression in whole blood, and *PINX1* (PIN2 (TERF1) interacting telomerase inhibitor 1) and *ERI1*

(exoribonuclease 1) had significant expression in lung, with strong evidence the same variant drives

expression and the CRF-slope association (PP4 range=0.71 – 0.98). *TRIP6*, *PINX1*, and *ERI1* have notably

been associated with blood pressure (63), triglyceride levels (64), HDL cholesterol (65), diabetes mellitus

(66), and atherosclerosis (67).

Additional TWAS significant functional candidates with high probability of the GWAS variant driving

expression included *SRRT* (serrate, RNA receptor molecule) in lung and heart (atrial appendage) tissue,

RP11-62H7.2 in heart (atrial appendage), *FAM86B3P* (family with sequence similarity 86 member B3) in

skeletal muscle, *FAM85B* (family with sequence similarity 85 member B) in lung and coronary artery, and

AF131215.2 in artery (coronary and tibial) (PP4 range=0.74 – 0.92). *SRRT* and *FAM86B3P* are notably

associated with heart rate response to exercise and recovery (59), electrocardiography (RR interval) (68),

diabetes mellitus (66), and obesity (69).

PA

All PA functional candidates were on chromosome 17, except *L3MBTL2* on chromosome 22. The number of

loci and the best candidates should be interpreted with caution as this is a gene dense region with many

copy number variants, and all the chromosome 17 candidates were within or near the large 17q21.3

inversion polymorphism (44, 45). Nonetheless, the positional candidates were supported by the functional

analyses.

Ten significant genes from the gene-based association analysis were identified as functional candidates:

PLEKHM1 (plekstrin homology domain containing M1) in lung, skeletal muscle, and peripheral blood with

low probability of the GWAS variant driving expression (PP4 range=0.30 – 0.33); *NSF* (N-Ethylmaleimide-

Sensitive Factor) in coronary artery (PP4=0.54); *MAPT* in subcutaneous adipose (PP4=0.91), artery (aorta

PP4=0.96, tibial PP4=0.67), and brain, left ventricle, lung, adipose (PP4 range=0.93 – 0.99); *LRRC37A2* in

adipose (visceral omentum and subcutaneous), artery (aorta, coronary), heart (atrial appendage and left

ventricle), lung (all PP4=0.99); *KANSL1* (KAT8 Regulatory NSL Complex Subunit 1) in skeletal muscle

(PP4=0.92); *CRHR1* in adipose (visceral omentum and subcutaneous) and skeletal muscle (PP4>=0.98);

ARL17A (ADP ribosylation factor like GTPase 17A) with high probability of a shared variant driving PA

association and gene expression in left ventricle (PP4=0.88) and skeletal muscle (PP4=0.97); *ARHGAP27* (rho

GTPase activating protein 27) in visceral omentum (PP4=0.92); and *L3MBTL2* (L3MBTL histone methyl-lysine

binding protein 2) in subcutaneous adipose (PP4=0.67).

Previous notable associations with these ten functional candidates include disease (Parkinson's disease

(70), hypertrophic cardio myopathy (71), ischaemic stroke, diabetes mellitus and coronary artery disease

(72)) anthropometrics (BMI-adjusted waist hip to ratio, BMI (73)), blood phenotypes (haemoglobin

measurement (55), red blood cell density, hematocrit (57), eosinophil count and systolic blood pressure

(54)), lung function (FVC (54), FEV1 (51)), and heart and electrocardiography measures (QRS measures (52),

cardiac arrhythmia (53)).

Figure 4 includes the full list of TWAS significant candidates, including those with lower posterior

probabilities of a shared variant driving both GWAS trait association and expression.

Gene set enrichment

We also performed gene set enrichment analyses on the TWAS significant genes for sex-combined CRF-

vo2max (16 genes), CRF-slope (10 genes) and PA (24 genes, 23 with recognized Ensembl ID), as well as

female PA (22 genes: 21 with recognized Ensembl ID). TWAS analyses of the other sex-specific traits did not

yield sufficient gene associations to perform enrichment analyses. Enrichment of TWAS-identified

functional candidates in gene sets defined by genes identified in previous GWASs, reported in the GWAS

Catalog, are shown in Additional file 1: **Figures S38–S40**.

Functional candidates for CRF-vo2max were enriched in GWAS gene sets for multiple diseases including
multiple system atrophy, Alzheimer's disease, Parkinson's disease, idiopathic pulmonary fibrosis, and
primary biliary cirrhosis (FDR-adjusted p range=6.9×10^{-3} – 2.0×10^{-5}), as well as lung function (FEV1, FDR-
adjusted p=) and blood phenotypes (haematocrit FDR-adjusted p values=2.8×10^{-2}, haemoglobin
concentration FDR-adjusted p values= 4.0×10^{-2}). Enrichment for genes implicated in Alzheimer's and
Parkinson's disease are noteworthy given there is some evidence of an underlying insulin resistance
pathology.
444
445 CRF-slope functional genes were enriched in GWAS gene sets for the thrombosis and atherosclerosis risk
446 factor *PAI-1* (plasminogen activator inhibitor-1: FDR-adjusted p=5.0×10^{-6}), heart rate response to exercise
447 and recovery (FDR-adjusted p=1.2×10^{-5}), and resting heart rate (FDR-adjusted p=1.4×10^{-3})
448
GWASs genes sets enriched for PA functional candidates included Parkinson's disease, idiopathic pulmonary
fibrosis, Alzheimer's disease, multiple system atrophy and primary biliary cirrhosis (FDR-adjusted p
range=2.7×10^{-2} – 2.0×10^{-8}), and mental health traits (e.g., neuroticism, mood instability, and alcohol use
disorder). Also noteworthy were enrichment of female PA-associated functional candidates in FEV1 (FDR-
adjusted p=4.1×10^{-4}) and FVC (FDR-adjusted p=3.1×10^{-3}) given their use in the diagnosis of obstructive and
restrictive pulmonary diseases.
455
456 **Genetic correlations within CRF-vo2max, CRF-slope, and PA**
457
458 CRF-vo2max, CRF-slope and PA were all polygenic with modest SNP heritabilities of between 0.08 and 0.14
459 (**Table 2**). There was no observed difference between sexes.
460
461 Table 2. Heritability of CRF and PA

	CRF-vo2max	CRF-slope	PA
Combined	0.10 (0.01)	0.08 (0.01)	0.14 (0.01)
Male	0.10 (0.01)	0.09 (0.02)	0.13 (0.01)
Female	0.11 (0.02)	0.10 (0.02)	0.15 (0.01)

462 Note. Values shown are SNP heritabilities and standard errors on the observed scale. CRF-vo2max =
463 maximum volume of oxygen uptake per kg of bodyweight per minute, estimated from workload and heart
464 rate during the cardiorespiratory fitness test, as well as age and weight; CRF-slope = the rate of increase of
465 heart rate during the exercise period of the cycle ramp test; PA = 7-day average physical activity
466
467
For the sex-combined between-phenotype genetic correlations, CRF-vo2max and CRF-slope were negatively
correlated (r_g=-0.66, se=0.04, p=5.4×10^{-53}), suggesting genetic variants that contribute to greater fitness
are also associated with a lower rate of increase of heart rate during exercise. PA had a moderate positive
correlation with CRF-vo2max (r_g=0.37, se=0.04, p=1.9×10^{-16}), and a modest negative correlation with CRF-
slope (r_g=-0.14, se=0.06, p=1.0×10^{-2}). These two genetic correlations suggest that higher levels of activity
have a shared genetic contribution with greater fitness, and with a lower rate of increase of heart rate

during exercise. The within-sex between-phenotype genetic correlations were similar to those for the sex-
combined results (Additional file 1: **Figure S41**). Within-phenotype between-sex genetic correlations were
all near 1.0, reflecting that the overall genomic signal is highly correlated despite a few different loci
between sexes (Additional file 1: **Figure S41**).

Genetic correlations with multiple traits and diseases

A comprehensive analysis of genetic correlations of CRF-vo2max, CRF-slope and PA with a wide array of
traits was performed using LD-HUB (**Figure 5** shows the combined-sex result, Additional file 1: **Figures S42**–
S44 show by-sex results). All genetic correlations described below were FDR-significant in the sex-
combined sample. Additional file 1: **Table S9** includes the sex-combined, male, and female FDR-significant
genetic correlations, as well as heritabilities, associated standard errors, and GWAS study PubMed IDs for
all FDR-significant traits and diseases.

Shared genetic risk: lipids, glycaemic and cardiometabolic traits

Genetic variation associated with lower CRF-vo2max was correlated with features of the typical type-2
diabetes (T2D) profile: higher insulin resistance (HOMA-IR: r_g=-0.58, se=0.12) and higher fasting insulin (r_g=-
0.45, se=0.09), impaired beta-cell function (HOMA-B: r_g=-0.40, se=0.09), hyperglycaemia (HbA1c: r_g=-0.25,
se=0.08) and hypertriglyceridemia (r_g=-0.17, se=0.04). In the PA combined sample, as well as genetic
correlations with fasting insulin (r_g=-0.31, se=0.07), insulin resistance (r_g=-0.29, se=0.07), and triglycerides
(r_g=-0.20, se=0.04), we observed a positive correlation with HDL cholesterol (r_g=0.28, se=0.04) and a direct
negative correlation with T2D (r_g=-0.23, se=0.05). Genetic variation associated with lower levels of physical
activity was associated with increased risk of T2D.

Both CRF-vo2max and PA were negatively correlated with coronary artery disease (CRF-vo2max r_g=-0.15,
se=0.05; PA r_g=-0.21, se=0.04). Like T2D, genetic variation associated with lower CRF-vo2max and lower PA
was associated with increased risk for coronary artery disease. Additional file 1: **Figure S45** highlights the
FDR-significant glycaemic, cardiometabolic, and lipid traits in the combined sample, as well as in males
and females separately.

Shared genetic risk: metabolites, hormones

CRF-vo2max was significantly genetically correlated with glycoprotein acetyls, GlycA (r_g=-029, se=0.10),
such that genetic variation associated with greater CRF-vo2max was associated with lower levels of the
GlycA biomarker. Elevated blood concentrations of GlycA are a strong predictor for long-term risk of
morbidity and mortality from diverse diseases (74).

For PA we observed positive FDR-significant genetic correlations with several related HDL metabolites. The
largest HDL metabolite correlation with PA was total cholesterol in medium HDL (r_g=0.42, se=0.15). Genetic

variation associated with greater CRF-vo2max and PA were associated with higher levels of HDL. PA was

also significantly correlated with acetate (r_g=0.36, se=0.13) and apolipoprotein A-I (r_g=0.35, se=0.12) – the

major protein component of HDL which enables fat efflux from within cells for transport to the liver for

excretion. Additional file 1: **Figure S50** shows the genetic correlations with blood metabolites for the

combined sample, and males and females separately.

Circulating levels of the satiety hormone leptin were negatively correlated with CRF-vo2max and PA (CRF-

vo2max r_g=-0.41, se=0.08; PA r_g=-0.37, se=0.07), and for BMI-adjusted leptin (CRF-vo2max r_g=-0.32,

se=0.08; PA r_g=-0.21, se=0.07) (Additional file 1: **Figure S45**). The genetic profile associated with greater

levels of fitness and activity is correlated with greater circulating levels of leptin, which inhibits hunger

and reduces fat storage in adipocytes.

Shared genetic risk: body measures

CRF-vo2max was positively genetically correlated with height (r_g=0.13, se=0.04), birth weight (r_g=0.14,

se=0.05) and own birth weight (r_g=0.13, se=0.04). All other FDR-significant anthropometric correlations

were negative (r_g range=-0.23 – -0.44, se range=0.04 – 0.07): body fat, waist circumference, measures of

obesity, BMI, waist-to-hip ratio and hip circumference. CRF-slope had FDR-significant negative genetic

correlations with childhood obesity (r_g=-0.24, se=0.06) and childhood height (r_g=-0.26, se=0.07), BMI (r_g=-

0.18, se=0.05), birth weight (r_g=-0.15, se=0.05) and own birth weight (r_g=-0.12, se=0.04). For PA, all FDR-

significant body measures including height were negative (r_g=-0.12 – -0.37, se=0.03 – 0.06): body fat, waist

circumference, measures of obesity, BMI, waist-to-hip ratio and hip circumference, and height. Genetic

variation associated with greater CRF-vo2max and higher levels of PA was associated with lower body fat,

BMI, obesity, and waist and hip circumferences. Additional file 1: **Figures S46-S48** show FDR-significant

genetic correlations with anthropometric measures for the combined sample and males and females

separately.

Shared genetic risk: lung function and heart rate

CRF-vo2max was positively associated with lung function: forced vital capacity (FVC: r_g=0.22 – 0.26, se=0.03

– 0.06), forced expiratory volume in 1 second (FEV1: r_g=0.18 – 0.24, se=0.03 – 0.07), and peak expiratory

flow (r_g=0.12, se=0.03). CRF-slope was negatively correlated with FVC (r_g=-0.13, se=0.04) and peak

expiratory flow (r_g=-0.14, se=0.04). For PA, we found modest positive genetic correlations with FVC

(r_g=0.13 – 0.15, se=0.03 – 0.04) and FEV1 (r_g=0.10, se=0.02). Genetic variation associated with both fitness

and activity is associated with improved lung function.

Only CRF-slope was genetically correlated with resting heart rate (r_g=-0.31, se=0.07). Genetic correlation

associated with greater acceleration of heart rate during exercise was associated a lower resting heart

rate. Additional file 1: **Figure S49** shows genetic correlations with lung function and heart rate, for the

combined sample and males and females separately.

Shared genetic risk: smoking behaviour and longevity

We observed a positive genetic correlation between PA and former vs current smoking status (r_g=0.27,
se=0.07). A genotype associated with greater levels of activity associated with smoking cessation.

Finally, we found that genetic variation associated with greater CRF-vo2max and PA was also significantly
associated with longevity, as measured by father's age at death (CRF-vo2max r_g=0.37, se=0.09; PA r_g=0.30,
se=0.07) and parents' ages at death (PA r_g=0.28, se=0.08). FDR-significant genetic correlations with
smoking behaviour, cancer and longevity reported above are highlighted in Additional file 1: **Figure S51**.

Shared genetic risk: demographics

CRF-vo2max and PA were positively correlated with years of schooling (CRF-vo2max r_g=0.28 – 0.32, se=0.04
– 0.05; PA r_g=0.11 – 0.14, se=0.03 – 0.04) and age at birth of first child (CRF-vo2max r_g=0.22, se=0.05; PA
r_g=0.13, se=0.04). CRF-slope had a corresponding negative genetic correlation with years of schooling (r_g=-
0.15 – -0.17, se=0.05). FDR-significant genetic correlations with education and reproductive phenotypes are
highlighted in Additional file 1: **Figure S52**.

Discussion

Genetic variation explains a modest but significant proportion of the variation in vo2max, rate of increase
of heart rate during exercise, and average weekly activity level, for both sexes. Genetic association signals
were highly correlated between sexes, with only six SNPs that showed evidence for a sex-specific
association (CRF-vo2max: rs1741294 male; CRF-slope: rs111299422 female, rs1741294 male; PA rs75986475,
rs13329850 female, rs78661713 male). The two derived fitness traits, CRF-vo2max (vo2max) and CRF-slope
(rate of increase of heart rate during exercise), were negatively correlated, phenotypically and genetically.
Greater levels of fitness corresponded to a slower rate of increase of heart rate during exercise. CRF-
vo2max was positively correlated with PA; greater fitness was associated with higher levels of physical
activity.

Lower CAD and T2D among most fit and active
587

We found that higher levels of CRF-vo2max and PA were associated with better health outcomes in a dose-
dependent way. The frequency of CAD and diabetes mellitus diagnosis was substantially lower among
individuals with higher levels of CRF-vo2max and PA, even after controlling for BMI and SES. In this large UK
population-based sample, we find the same associations between PA and CRF-vo2max observed in
epidemiological and clinical studies of coronary heart disease and cardiovascular events (75) and T2D (76).
As has been previously observed (3), there was a noteworthy steeper drop-off in disease occurrence with

increased PA and CRF-vo2max among the least fit and active third of the sample. The fitness and activity
associations with disease observed in the combined sample were most stark among males. For CRF-vo2max
and CRF-slope, disease diagnosis frequency was generally lower as we only included individuals with no
contraindications for the standard cycle ramp test protocol. Disease diagnosis association with CRF-slope
was noisy, with no clear pattern of association except for a small reduction in CAD and diabetes mellitus. It
is not clear why there would be a reduction in disease diagnoses with increasing CRF-slope, given the
negative correlation with CRF-vo2max. One possible factor is that among the participants with high CRF-
slope levels there is a mix of the least fit samples whose heart rates increased by a larger amount during
exercise, participants with lower resting heart rates due to medical conditions and medication (expected to
be low given risk category exclusions), and the most fit samples who would have lower resting heart rates.
604
605 **Disease associated genes implicated in CRF and PA**
606
Our functional genetic analyses identified genes associated with CRF and PA, with known associations in
disease and clinical vital sign related phenotypes. For CRF-vo2max, we found functional candidates
associated with expression in heart, artery, lung, brain, adipose, and skeletal muscle. All functional
candidates were within 17q21.31, with five genes also identified in the gene-based association analysis
(*WNT3, MAPT, LRRC37A2, LRRC37A, CRHR1*). These five genes have previously been associated with GWASs
for atrial fibrillation (46), diabetes mellitus, and coronary artery disease (47), Parkinson's (48), and
Alzheimer's disease (49), lung function (FEV1, FVC (50), peak expiratory flow (51)), heart and
electrocardiography measures (52), cardiac arrhythmia (53), and blood phenotypes (systolic blood pressure,
eosinophil count (54), haemoglobin level (55), haematocrit (56), red blood cell density (57)). Subsets of
CRF-vo2max functional candidates were enriched in the GWAS catalog for multiple system atrophy,
Alzheimer's disease, Parkinson's disease, idiopathic pulmonary fibrosis, primary biliary cirrhosis, FEV1,
haematocrit, and haemoglobin concentration.
619
For CRF-slope, functional candidates fell within one of two cytogenic regions, 7q21.1 and 8p23.1. *ACHE*
within 7q21.1, also identified as a positional candidate 52.87kb upstream of rs4582488, was significantly
associated with expression in adipose, artery and heart tissue, and has previously been associated with
resting heart rate (58), heart rate response to exercise and recovery (59), electrocardiography (60),
diastolic blood pressure (61), and diabetes mellitus (62). The gene-based association identified genes
(*TRIP6, PINX1,* and *ERI1*) were significantly associated with expression change in whole blood and lung, and
have previously been associated with blood pressure (63), triglyceride levels (64), HDL cholesterol (65),
diabetes mellitus (66), and atherosclerosis (67). Other promising functional candidates (*SRRT, RP11-62H7.2,*
FAM86B3P, FAM85B, and *AF131215.2*) were associated with expression in lung, heart, skeletal muscle, and
coronary and tibial artery, and have been associated in previous GWASs with heart rate response to
exercise and recovery (59), electrocardiography (68), diabetes mellitus (66), and obesity (69). We found
subsets of the CRF-slope functional candidates were enriched in GWAS gene sets for the thrombosis and
atherosclerosis risk factor *PAI-1,* heart rate response to exercise and recovery, and resting heart rate.
633

For PA, the functional candidates on 17q21.31 (*MAPT, LRRC37A2, LRRC37A, KANSL1, CRHR1, ARL17A,* and
ARHGAP27) and 22q13.2 (*L3MBTL2*) with a high probability of the same variant driving PA association and
expression in adipose, brain, heart, lung and muscle, have previously been associated with disease
(Parkinson's disease (70), hypertrophic cardio myopathy (71), ischaemic stroke, diabetes mellitus and
coronary artery disease (72)) anthropometrics (BMI-adjusted waist hip to ratio, BMI (73)), blood phenotypes
(haemoglobin measurement (55), red blood cell density, hematocrit (57), eosinophil count and systolic
blood pressure (54)), lung function (FVC (54), FEV1 (51)), and heart and electrocardiography measures (QRS
measures (52), cardiac arrhythmia (53)). We found PA functional candidates enriched in Parkinson's and
Alzheimer's disease, noteworthy given their underlying insulin resistance pathology (although the insulin
resistance link is controversial for Alzheimer's disease), idiopathic pulmonary fibrosis, multiple system
atrophy and primary biliary cirrhosis. Functional candidates from the female PA GWAS were also enriched
in the lung function phenotypes FEV1 and FVC.

Genetic correlations link CRF and PA with disease

Genetic correlations complement epidemiological and clinical observations. Because inherited genetic risk
cannot be due to confounding, genetic correlations limit the number of potential confounders linked
through genotype. The shared genetic architecture of both CRF-vo2max and PA clearly implicated the
lifestyle-related chronic diseases obesity, T2D, and CAD, and their body composition and metabolic risk
factors. CRF-vo2max and PA were negatively genetically correlated with obesity, body fat, body mass
index, and waist-to-hip circumference, triglycerides, the satiety hormone leptin, fasting insulin, insulin
resistance, and T2D (significant only for PA), and CAD. These negative genetic correlations corroborate the
epidemiological associations, previous research findings, and clinical observations of CRF and PA and body
composition (77, 78), lipid profile (79, 80), adipocytokines (81), fasting insulin and insulin resistance (82-
86) and leptin (76), T2D (87-89), and CAD (90). Likewise, the positive genetic correlations are consistent
with previous observations of positive relationships between CRF and PA, and HDL cholesterol (80, 91) and
longevity (92-94).

CRF-vo2max was negatively genetically correlated with blood levels of glycoprotein acetyls (GlycA). GlycA
is associated with both acute and chronic inflammation and is a strong predictor for long-term risk of
morbidity and mortality from a wide range of diseases (74).

Additionally, CRF-vo2max and PA had positive genetic correlations with age at birth of first child and level
of education, respectively a correlate and component of SES. CRF-slope showed a corresponding negative
correlation with years of education. This is consistent with population-based observations of a
socioeconomic gradient in PA and CRF: people living in higher socioeconomic status areas tend to be more
active and more fit, and from a public health perspective particularly important as "reduced PA and fitness
levels may contribute to social inequalities in health" (95).

We note several limitations. The gold standard for CRF measurement involves exercise to volitional
exhaustion with measurement of gas exchange (uptake of oxygen, elimination of carbon dioxide). A
submaximal CRF test with extrapolation of VO2max scores is however a much more practical solution,
especially for the collection of a large sample in the age ranges studied. The objective PA monitoring only
captured a 7-day window, effectively a snapshot of participant behaviour, and we do not know if this
reflects their habitual behaviour. We also used raw acceleration and did not attempt to tease apart PA
intensity, recognized as important for health outcomes. All genetic associations, especially the sex-specific
SNPs identified, will require replication in an independent sample. In our genetic correlation analyses,
some of the largest correlations were observed with blood metabolites but these were based on relatively
small GWAS reference samples (metabolites N=24,925 compared to body fat N=100,716) and many
metabolite correlations failed to pass the multiple testing threshold. As well as this sample size (or power
of each discovery GWAS) limitation, genetic correlations cannot resolve reverse causation. Another
limitation is correlated lifestyle risk factors not considered, in particular eating behaviours and nutrition.
Eating habits, diet, and exercise behaviours tend to go hand in hand, in large part influenced by the
environment, e.g., sedentary time spent watching television and eating high-fat foods (96, 97). A holistic
approach to health – addressing eating habits and including an effective dietary intervention (98),
alongside prescription PA and monitoring of CRF – may be the most effective practical approach, especially
in already overweight individuals given the possibility that there exists a bi-directional relationship
between adiposity and PA (99). Despite the complex interplay of eating habits, nutrition, environment, and
PA, CRF as a regularly measured vital sign is an objective and easily measured sentinel for health.
693
694
695 **Conclusions**
696
In summary, we found strong evidence that genetic variants associated with CRF and PA also influenced
genetic expression in a small set of genes in heart, artery, brain, lung, muscle, and adipose tissue. These
functionally relevant genes were enriched among genes known to be associated with CAD, T2D and
Alzheimer's disease – three of the top 10 causes of death in high-income countries – as well as Parkinson's,
pulmonary fibrosis, and blood pressure, heart rate, and respiratory phenotypes. Finally, genetic correlation
related lower fitness and activity with several disease risk factors including greater waist-to-hip ratio, BMI,
and obesity; with a typical T2D profile including higher insulin resistance, higher fasting glucose, impaired
beta-cell function, hyperglycaemia, hypertriglyceridemia; increased risk for CAD and T2D; and shorter
lifespan. Genetics supports three decades of evidence for the inclusion of CRF as a clinical vital sign (3).
CRF is a window onto general health and wellbeing, and physical activity is the primary means of improving
CRF. In fact, to meet the WHO policy of reduction in sedentary lifestyles that carry a heavy cost to personal
and public health, "policies to increase population levels of physical activity need to be prioritised and
scaled up urgently" (9). PA too is "vital"; we think both measures provide important information and
ideally should be collected in tandem if feasible. Given the global health burden of non-communicable
disease related to lifestyle choices, as well as dietary advice, regular measurement of CRF as a marker of
health and routine prescription of PA is imperative.

Figure captions

Figure 1. Heart rate signal processing for a single random sample. Trend = repeated measurements
within the 'Exercise' phase of the submaximal cycle ramp test; Raw = unaltered heart rate data;
Butterworth filtered = heart rate data after low-pass Butterworth filter (heart rate at the beginning and
end of the exercise period on this filtered signal used to calculate CRF-vo2max); Linear model = fitted
heart rate data values from a linear model fitted to the Butterworth filtered signal (CRF-slope is the slope
of this linear model).

Figure 2. ICD-10 diagnosis frequency by CRF and PA level. Frequency in the UKB for the top 10 global
causes of death in high-income countries in 2016, as reported by the World Health Organization (WHO,
Additional file 1: **Table S3**). The CRF and PA phenotypes above were controlled for age and socioeconomic
status (SES, the Townsend deprivation index) – they are the residuals from a regression on age and SES. For
some diseases, e.g., breast cancer, disease trends are only meaningful separated by sex. CAD = ischaemic
heart disease; STR = stroke; ALZ = Alzheimer's disease and other dementias; LCX = trachea, bronchus and
lung cancers; COPD = chronic obstructive pulmonary disease; LRTI = lower respiratory tract infections; CCX
= colon and rectum cancers; DIA = diabetes mellitus; KID = kidney diseases; BCX = breast cancers

Figure 3. Genome-wide association signal by sex for CRF-vo2max, CRF-slope, and PA. The red line shows
genome-wide significance, $p=5x10^{-8}$.

Figure 4. TWAS and colocalization identified genes. Genes listed on the y-axes are significant at the
conservative Bonferroni corrected TWAS p-value. On the x-axis is tissue type; category of tissue is
represented by colour, colocalization posterior probability 4 (COLOC PP4 – the probability of a shared
causal SNP driving the association signal and expression in a reference tissue) represented by line angle
(vertical line is a probability of 1.0 that the GWAS-identified SNP is an eQTL for the gene). The
complementary TWAS and colocalization approaches provide a priority list of genes for further exploration.
Genes in bold were significant in the gene-based test of association.

Figure 5. Genetic correlations for combined males and females. red = negative correlations; blue =
positive correlations; size = relative size of the genetic correlation; Bonferroni threshold shows
p=0.05/total number of correlations per trait; False discovery rate threshold indicates the largest FDR-
adjusted p-value < 0.05

List of abbreviations

CRF = cardiorespiratory fitness, PA = physical activity, AHA = American Heart Association, UKB = UK

Biobank, CRF-vo2max = an estimate of the participants' maximum volume of oxygen uptake, per kilogram of

body weight, per minute, CRF-slope = an estimate of the rate of increase of heart rate during exercise,

GWAS = genome-wide association study, CAD = coronary artery disease/ ischaemic heart disease, T2D =

type 2 diabetes, h^2 = heritability, h^2_{SNP} = SNP heritability, ECG = electrocardiograph, BMI = body mass index,

HR = heart rate, WL = workload, WHO = world health organization, ICD-10 = International Classification of

Diseases revision 10, SES = socioeconomic status, TWAS = transcriptome-wide association, FDR = false-

discovery rate, eQTL = expression quantitative trait locus, PP4 = posterior probability 4

Declarations

Ethics approval and consent to participate

Ethics approval for the UK Biobank study was obtained from the North West Centre for Research Ethics

Committee (11/NW/0382); participants provided electronic signed consent at recruitment. This research

has been conducted under application number 13427.

Consent for publication

Not applicable.

Availability of data and materials

The data that support the findings of this study are available upon application to the UK Biobank (UKB). The

UKB database is globally accessible to approved researchers.

Competing interests

The authors declare that they have no competing interests.

Funding

This research was funded by the National Institute for Health Research (NIHR) Biomedical Research Centre

(BRC) South London and Maudsley, and Guy's and St Thomas', NHS Foundation Trusts, and King's College

London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the

Department of Health and Social Care. CML receives funding from a UK Medical Research Council (MRC)

grant (MR/N015746/1).

Authors' contributions

KBH, MH, CML conceived and designed the study. KBH analysed the data. KBH, EP, MT, KPG, MH, JRIC, CML

interpreted the results and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We would like to acknowledge the UKB participants for their contributions.

Additional files

Additional file 1

Additional file 1.docx includes supplementary Methods (genetic data quality control, GWAS considerations,

alternate genetic association models, and post GWAS details), Results (including alternate association

models, GWAS post-processing), Tables S1 – S9, and Figures S1 – S52.

References

1.   DeFina LF, Haskell WL, Willis BL, Barlow CE, Finley CE, Levine BD, et al. Physical activity versus

cardiorespiratory fitness: two (partly) distinct components of cardiovascular health? Prog Cardiovasc Dis.

2015;57(4):324-9.

2.   Lavie CJ, Johannsen N, Swift D, Senechal M, Earnest C, Church T, et al. Exercise is Medicine - The

Importance of Physical Activity, Exercise Training, Cardiorespiratory Fitness and Obesity in the Prevention

and Treatment of Type 2 Diabetes. Eur Endocrinol. 2014;10(1):18-22.

3.   Ross R, Blair SN, Arena R, Church TS, Despres JP, Franklin BA, et al. Importance of Assessing

Cardiorespiratory Fitness in Clinical Practice: A Case for Fitness as a Clinical Vital Sign: A Scientific

Statement From the American Heart Association. Circulation. 2016;134(24):e653-e99.

4.   Stamatakis E, Hamer M, O'Donovan G, Batty GD, Kivimaki M. A non-exercise testing method for

estimating cardiorespiratory fitness: associations with all-cause and cardiovascular mortality in a pooled

analysis of eight population-based cohorts. Eur Heart J. 2013;34(10):750-8.

5.   Tipton CM. The history of "Exercise Is Medicine" in ancient civilizations. Adv Physiol Educ.

2014;38(2):109-17.

6.   Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000.
JAMA. 2004;291(10):1238-45.

7.   Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT, et al. Effect of physical inactivity
on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy.
Lancet. 2012;380(9838):219-29.

8.   Ding D, Lawson KD, Kolbe-Alexander TL, Finkelstein EA, Katzmarzyk PT, van Mechelen W, et al. The
economic burden of physical inactivity: a global analysis of major non-communicable diseases. Lancet.
2016;388(10051):1311-24.

9.   Guthold R, Stevens GA, Riley LM, Bull FC. Worldwide trends in insufficient physical activity from
2001 to 2016: a pooled analysis of 358 population-based surveys with 1.9 million participants. Lancet Glob
Health. 2018;6(10):e1077-e86.

10.   British Heart Foundation Physical Inactivity Report 2017 [Available from:
https://www.bhf.org.uk/informationsupport/publications/statistics/physical-inactivity-report-2017]

11.   Teran-Garcia M, Rankinen T, Bouchard C. Genes, exercise, growth, and the sedentary, obese child.
J Appl Physiol (1985). 2008;105(3):988-1001.

12.   den Hoed M, Brage S, Zhao JH, Westgate K, Nessa A, Ekelund U, et al. Heritability of objectively
assessed daily physical activity and sedentary behavior. Am J Clin Nutr. 2013;98(5):1317-25.

13.   Timmons JA, Knudsen S, Rankinen T, Koch LG, Sarzynski M, Jensen T, et al. Using molecular
classification to predict gains in maximal aerobic capacity following endurance exercise training in humans.
J Appl Physiol (1985). 2010;108(6):1487-96.

14.   Bouchard C, Sarzynski MA, Rice TK, Kraus WE, Church TS, Sung YJ, et al. Genomic predictors of the
maximal O(2) uptake response to standardized exercise training programs. J Appl Physiol (1985).
2011;110(5):1160-70.

15.   Williams CJ, Williams MG, Eynon N, Ashton KJ, Little JP, Wisloff U, et al. Genes to predict VO2max
trainability: a systematic review. BMC Genomics. 2017;18(Suppl 8):831.

16.   Klimentidis YC, Raichlen DA, Bea J, Garcia DO, Wineinger NE, Mandarino LJ, et al. Genome-wide
association study of habitual physical activity in over 377,000 UK Biobank participants identifies multiple
variants including CADM2 and APOE. Int J Obes (Lond). 2018.

17.   Doherty A, Smith-Bryne K, Ferreira T, Holmes MV, Holmes C, Pulit S, et al. GWAS identifies 14 loci
for device-measured physical activity and sleep duration. Nature Communications. 2018;9(5257).

18.   Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with
deep phenotyping and genomic data. Nature. 2018;562(7726):203-9.

19.   Wilson MG, Ellison GM, Cable NT. Basic science behind the cardiovascular benefits of exercise. Brit
J Sport Med. 2016;50(2):93-+.

20.   Karastergiou K, Smith SR, Greenberg AS, Fried SK. Sex differences in human adipose tissues - the
biology of pear shape. Biol Sex Differ. 2012;3.

21.   Valencak TG, Osterrieder A, Schulz TJ. Sex matters: The effects of biological sex on adipose tissue
biology and energy metabolism. Redox Biol. 2017;12:806-13.

22.   van Uffelen JGZ, Khan A, Burton NW. Gender differences in physical activity motivators and
context preferences: a population-based study in people in their sixties. BMC Public Health.
2017;17(1):624.

23.   Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access
resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med.
2015;12(3):e1001779.

24.   UK Biobank Cardio Assessment Version 1.0 [Available from:
https://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/Cardio.pdf]

25.   Celis-Morales CA, Lyall DM, Anderson J, Iliodromiti S, Fan Y, Ntuk UE, et al. The association
between physical activity and risk of mortality is modulated by grip strength and cardiorespiratory fitness:
evidence from 498 135 UK-Biobank participants. Eur Heart J. 2017;38(2):116-22.

26.   Tanaka H, Monahan KD, Seals DR. Age-predicted maximal heart rate revisited. J Am Coll Cardiol.
2001;37(1):153-6.

27.   Swain DP. Energy cost calculations for exercise prescription: an update. Sports Med. 2000;30(1):17-
22.

28.   Kim Y, White T, Wijndaele K, Westgate K, Sharp SJ, Helge JW, et al. The combination of
cardiorespiratory fitness and muscle strength, and mortality risk. Eur J Epidemiol. 2018;33(10):953-64.

29.   Doherty A, Jackson D, Hammerla N, Plotz T, Olivier P, Granat MH, et al. Large Scale Population
Assessment of Physical Activity Using Wrist Worn Accelerometers: The UK Biobank Study. PLoS One.
2017;12(2):e0169649.

30.   UK Biobank Resource 664 [Available from: http://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=664.]

31.   R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical
Computing, Vienna, Austria. https://www.R-project.org/.

32.   Van Rossum G, Drake FL. Python 3 Reference Manual. Scotts Valley, CA: CreateSpace; 2009.

33.   Koster J, Rahmann S. Snakemake--a scalable bioinformatics workflow engine. Bioinformatics.
2012;28(19):2520-2.

34.   Hanscombe KB, Coleman RI, Traylor M, Lewis CM. ukbtools: An R package to manage and query UK
Biobank data. PLoS One. 2019.

35.   Abraham G, Qiu Y, Inouye M. FlashPCA2: principal component analysis of Biobank-scale genotype
datasets. Bioinformatics. 2017;33(17):2776-8.

36.   Loh PR, Tucker G, Bulik-Sullivan BK, Vilhjalmsson BJ, Finucane HK, Salem RM, et al. Efficient
Bayesian mixed-model analysis increases association power in large cohorts. Nat Genet. 2015;47(3):284-90.

37.   Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to
the challenge of larger and richer datasets. Gigascience. 2015;4:7.

38.   Bulik-Sullivan BK, Loh P-R, Finucane HK, Ripke S, Yang J, Schizophrenia Working Group of the
Psychiatric Genomics C, et al. LD Score regression distinguishes confounding from polygenicity in genome-
wide association studies. Nature Genetics. 2015;47:291.

39.   Gusev A, Ko A, Shi H, Bhatia G, Chung W, Penninx BW, et al. Integrative approaches for large-scale
transcriptome-wide association studies. Nat Genet. 2016;48(3):245-52.

40.   Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of
genetic associations with FUMA. Nat Commun. 2017;8(1):1826.

41.   Zheng J, Erzurumluoglu AM, Elsworth BL, Kemp JP, Howe L, Haycock PC, et al. LD Hub: a
centralized database and web interface to perform LD score regression that maximizes the potential of
summary level GWAS data for SNP heritability and genetic correlation analysis. Bioinformatics.
2017;33(2):272-9.

42.   Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific
haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics.
2015;31(21):3555-7.

43.   Aschard H, Vilhjalmsson BJ, Joshi AD, Price AL, Kraft P. Adjusting for heritable covariates can bias
effect estimates in genome-wide association studies. Am J Hum Genet. 2015;96(2):329-39.

44.   Stefansson H, Helgason A, Thorleifsson G, Steinthorsdottir V, Masson G, Barnard J, et al. A common
inversion under selection in Europeans. Nat Genet. 2005;37(2):129-37.

45.   Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, et al. Identification and
molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun.
2013;4:1627.

46.   Nielsen JB, Thorolfsdottir RB, Fritsche LG, Zhou W, Skov MW, Graham SE, et al. Biobank-driven
genomic discovery yields new insight into atrial fibrillation biology. Nat Genet. 2018;50(9):1234-9.

47.   van der Harst P, Verweij N. Identification of 64 Novel Genetic Loci Provides an Expanded View on
the Genetic Architecture of Coronary Artery Disease. Circ Res. 2018;122(3):433-43.

48.   Pankratz N, Beecham GW, DeStefano AL, Dawson TM, Doheny KF, Factor SA, et al. Meta-analysis of
Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol. 2012;71(3):370-84.

49.   Jun G, Ibrahim-Verbaas CA, Vronskaya M, Lambert JC, Chung J, Naj AC, et al. A novel Alzheimer
disease locus located near the gene encoding tau protein. Mol Psychiatry. 2016;21(1):108-17.

50.   Wyss AB, Sofer T, Lee MK, Terzikhan N, Nguyen JN, Lahousse L, et al. Multiethnic meta-analysis
identifies ancestry-specific and cross-ancestry loci for pulmonary function. Nat Commun. 2018;9(1):2976.

51.   Shrine N, Guyatt AL, Erzurumluoglu AM, Jackson VE, Hobbs BD, Melbourne CA, et al. New genetic
signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across
multiple ancestries. Nat Genet. 2019;51(3):481-93.

52.   van der Harst P, van Setten J, Verweij N, Vogler G, Franke L, Maurano MT, et al. 52 Genetic Loci
Influencing Myocardial Mass. J Am Coll Cardiol. 2016;68(13):1435-48.

53.   Ishigaki K, Akiyama M, Kanai M, Takahashi A, Kawakami E, Sugishita H, et al. Large-scale genome-
wide association study in a Japanese population identifies novel susceptibility loci across different diseases.
Nat Genet. 2020;52(7):669-79.

54.   Kichaev G, Bhatia G, Loh PR, Gazal S, Burch K, Freund MK, et al. Leveraging Polygenic Functional
Enrichment to Improve GWAS Power. Am J Hum Genet. 2019;104(1):65-75.

55.   Oskarsson GR, Oddsson A, Magnusson MK, Kristjansson RP, Halldorsson GH, Ferkingstad E, et al.
Predicted loss and gain of function mutations in ACO1 are associated with erythropoiesis. Commun Biol.
2020;3(1):189.

56.   Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, et al. The Allelic Landscape of Human
Blood Cell Trait Variation and Links to Common Complex Disease. Cell. 2016;167(5):1415-29 e19.

57.   Chen MH, Raffield LM, Mousas A, Sakaue S, Huffman JE, Moscati A, et al. Trans-ethnic and
Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals from 5 Global Populations. Cell.
2020;182(5):1198-213 e14.

58.   Ramirez J, Duijvenboden SV, Ntalla I, Mifsud B, Warren HR, Tzanis E, et al. Thirty loci identified for
heart rate response to exercise and recovery implicate autonomic nervous system. Nat Commun.
2018;9(1):1947.

59.   Verweij N, van de Vegte YJ, van der Harst P. Genetic study links components of the autonomous
nervous system to heart-rate profile during exercise. Nat Commun. 2018;9(1):898.

60.   Verweij N, Benjamins JW, Morley MP, van de Vegte YJ, Teumer A, Trenkwalder T, et al. The
Genetic Makeup of the Electrocardiogram. Cell Syst. 2020;11(3):229-38 e5.

61.   Giri A, Hellwege JN, Keaton JM, Park J, Qiu C, Warren HR, et al. Trans-ethnic association study of
blood pressure determinants in over 750,000 individuals. Nat Genet. 2019;51(1):51-62.

62.   Sim X, Ong RT, Suo C, Tay WT, Liu J, Ng DP, et al. Transferability of type 2 diabetes implicated loci
in multi-ethnic cohorts from Southeast Asia. PLoS Genet. 2011;7(4):e1001363.

63.   Warren HR, Evangelou E, Cabrera CP, Gao H, Ren M, Mifsud B, et al. Genome-wide association
analysis identifies novel blood pressure loci and offers biological insights into cardiovascular risk. Nat
Genet. 2017;49(3):403-15.

64.   Ripatti P, Ramo JT, Mars NJ, Fu Y, Lin J, Soderlund S, et al. Polygenic Hyperlipidemias and
Coronary Artery Disease Risk. Circ Genom Precis Med. 2020;13(2):e002725.

65.   Richardson TG, Sanderson E, Palmer TM, Ala-Korpela M, Ference BA, Davey Smith G, et al.
Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary
heart disease: A multivariable Mendelian randomisation analysis. PLoS Med. 2020;17(3):e1003062.

66.   Xue A, Wu Y, Zhu Z, Zhang F, Kemper KE, Zheng Z, et al. Genome-wide association analyses
identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes. Nat Commun.
2018;9(1):2941.

67.   Bis JC, Kavousi M, Franceschini N, Isaacs A, Abecasis GR, Schminke U, et al. Meta-analysis of
genome-wide association studies from the CHARGE consortium identifies common variants associated with
carotid intima media thickness and plaque. Nat Genet. 2011;43(10):940-7.

68.   van Setten J, Verweij N, Mbarek H, Niemeijer MN, Trompet S, Arking DE, et al. Genome-wide
association meta-analysis of 30,000 samples identifies seven novel loci for quantitative ECG traits. Eur J
Hum Genet. 2019;27(6):952-62.

69.   Schlauch KA, Read RW, Lombardi VC, Elhanan G, Metcalf WJ, Slonim AD, et al. A Comprehensive
Genome-Wide and Phenome-Wide Examination of BMI and Obesity in a Northern Nevadan Cohort. G3
(Bethesda). 2020;10(2):645-64.

70.   Edwards TL, Scott WK, Almonte C, Burt A, Powell EH, Beecham GW, et al. Genome-wide association
study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum
Genet. 2010;74(2):97-109.

71.   Tadros R, Francis C, Xu X, Vermeer AMC, Harper AR, Huurman R, et al. Shared genetic pathways
contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nat
Genet. 2021;53(2):128-34.

72.   Song Y, Choi JE, Kwon YJ, Chang HJ, Kim JO, Park DH, et al. Identification of susceptibility loci for
cardiovascular disease in adults with hypertension, diabetes, and dyslipidemia. J Transl Med.
2021;19(1):85.

73.   Zhu Z, Guo Y, Shi H, Liu CL, Panganiban RA, Chung W, et al. Shared genetic and experimental links
between obesity-related traits and asthma subtypes in UK Biobank. J Allergy Clin Immunol.
2020;145(2):537-49.

74.   Kettunen J, Ritchie SC, Anufrieva O, Lyytikainen LP, Hernesniemi J, Karhunen PJ, et al. Biomarker
Glycoprotein Acetyls Is Associated With the Risk of a Wide Spectrum of Incident Diseases and Stratifies
Mortality Risk in Angiography Patients. Circ Genom Precis Med. 2018;11(11):e002234.

75.   Kodama S, Saito K, Tanaka S, Maki M, Yachi Y, Asumi M, et al. Cardiorespiratory fitness as a
quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-
analysis. JAMA. 2009;301(19):2024-35.

76.   Lin X, Zhang X, Guo J, Roberts CK, McKenzie S, Wu WC, et al. Effects of Exercise Training on
Cardiorespiratory Fitness and Biomarkers of Cardiometabolic Health: A Systematic Review and Meta-
Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2015;4(7).

77.   L. dL, R. R. Physical Activity, Cardiorespiratory Fitness, and Obesity. In: P. K, P. N, editors.
Cardiorespiratory Fitness in Cardiometabolic Diseases: Springer; 2019.

78.   Prioreschi A, Brage S, Westgate K, Norris SA, Micklesfield LK. Cardiorespiratory fitness levels and
associations with physical activity and body composition in young South African adults from Soweto. BMC
Public Health. 2017;17(1):301.

79.   Sui X, Sarzynski MA, Lee DC, Kokkinos PF. Impact of Changes in Cardiorespiratory Fitness on
Hypertension, Dyslipidemia and Survival: An Overview of the Epidemiological Evidence. Prog Cardiovasc Dis.
2017;60(1):56-66.

80.   Breneman CB, Polinski K, Sarzynski MA, Lavie CJ, Kokkinos PF, Ahmed A, et al. The Impact of
Cardiorespiratory Fitness Levels on the Risk of Developing Atherogenic Dyslipidemia. Am J Med.
2016;129(10):1060-6.

81.   Martinez-Gomez D, Eisenmann JC, Gomez-Martinez S, Veses A, Romeo J, Veiga OL, et al.
Associations of physical activity and fitness with adipocytokines in adolescents: the AFINOS Study. Nutr
Metab Cardiovasc Dis. 2012;22(3):252-9.

82.   Bird SR, Hawley JA. Update on the effects of physical activity on insulin sensitivity in humans. BMJ
Open Sport Exerc Med. 2016;2(1):e000143.

83.   Henderson M, Benedetti A, Barnett TA, Mathieu ME, Deladoey J, Gray-Donald K. Influence of
Adiposity, Physical Activity, Fitness, and Screen Time on Insulin Dynamics Over 2 Years in Children. JAMA
Pediatr. 2016;170(3):227-35.

84.   Gill JM. Physical activity, cardiorespiratory fitness and insulin resistance: a short update. Curr Opin
Lipidol. 2007;18(1):47-52.

85.   Hamer M, O'Donovan G. Cardiorespiratory fitness and metabolic risk factors in obesity. Curr Opin
Lipidol. 2010;21(1):1-7.

86.   Nystrom CD, Henriksson P, Martinez-Vizcaino V, Medrano M, Cadenas-Sanchez C, Arias-Palencia NM,
et al. Does Cardiorespiratory Fitness Attenuate the Adverse Effects of Severe/Morbid Obesity on
Cardiometabolic Risk and Insulin Resistance in Children? A Pooled Analysis. Diabetes Care.
2017;40(11):1580-7.

87.   Aune D, Norat T, Leitzmann M, Tonstad S, Vatten LJ. Physical activity and the risk of type 2
diabetes: a systematic review and dose-response meta-analysis. Eur J Epidemiol. 2015;30(7):529-42.

88.   Rohling M, Strom A, Bonhof G, Puttgen S, Bodis K, Mussig K, et al. Differential Patterns of Impaired
Cardiorespiratory Fitness and Cardiac Autonomic Dysfunction in Recently Diagnosed Type 1 and Type 2
Diabetes. Diabetes Care. 2017;40(2):246-52.

89.   Juraschek SP, Blaha MJ, Blumenthal RS, Brawner C, Qureshi W, Keteyian SJ, et al. Cardiorespiratory
fitness and incident diabetes: the FIT (Henry Ford ExercIse Testing) project. Diabetes Care.
2015;38(6):1075-81.

90.   Myers J, McAuley P, Lavie CJ, Despres JP, Arena R, Kokkinos P. Physical activity and
cardiorespiratory fitness as major markers of cardiovascular risk: their independent and interwoven
importance to health status. Prog Cardiovasc Dis. 2015;57(4):306-14.

91.   O'Donovan G, Hillsdon M, Ukoumunne OC, Stamatakis E, Hamer M. Objectively measured physical
activity, cardiorespiratory fitness and cardiometabolic risk factors in the Health Survey for England. Prev
Med. 2013;57(3):201-5.

92.   Moore SC, Patel AV, Matthews CE, Berrington de Gonzalez A, Park Y, Katki HA, et al. Leisure time
physical activity of moderate to vigorous intensity and mortality: a large pooled cohort analysis. PLoS Med.
2012;9(11):e1001335.

93.   Mandsager K, Harb S, Cremer P, Phelan D, Nissen SE, Jaber W. Association of Cardiorespiratory
Fitness With Long-term Mortality Among Adults Undergoing Exercise Treadmill Testing. JAMA Netw Open.
2018;1(6):e183605.

94.   Chudasama YV, Khunti KK, Zaccardi F, Rowlands AV, Yates T, Gillies CL, et al. Physical activity,
multimorbidity, and life expectancy: a UK Biobank longitudinal study. BMC Med. 2019;17(1):108.

95.   Lindgren M, Borjesson M, Ekblom O, Bergstrom G, Lappas G, Rosengren A. Physical activity pattern,
cardiorespiratory fitness, and socioeconomic status in the SCAPIS pilot trial - A cross-sectional study. Prev
Med Rep. 2016;4:44-9.

96.   Hill JO, Peters JC. Environmental contributions to the obesity epidemic. Science.
1998;280(5368):1371-4.

97.   French SA, Story M, Jeffery RW. Environmental influences on eating and physical activity. Annu Rev
Public Health. 2001;22:309-35.

98.   Wright N, Wilson L, Smith M, Duncan B, McHugh P. The BROAD study: A randomised controlled trial

using a whole food plant-based diet in the community for obesity, ischaemic heart disease or diabetes. Nutr

Diabetes. 2017;7(3):e256.

99.   Richmond RC, Davey Smith G, Ness AR, den Hoed M, McMahon G, Timpson NJ. Assessing causality in

the association between child adiposity and physical activity levels: a Mendelian randomization analysis.

PLoS Med. 2014;11(3):e1001618.

1061

1062